A Phase 2 Study of LTX-315 in Combination with Pembrolizumab in Patients with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy (ATLAS-IT-05)

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Lytix Biopharma AS

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

24 Oct 2022 → 1 Jul 2025

Decision date (initial)

2022-08-26

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

Yes

Funding sources

Lytix

External identifiers

EU CT number

2022-500628-31-00

ClinicalTrials.gov

NCT04796194

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Pharmacokinetic, Efficacy, Safety

To evaluate preliminary antitumor activity of LTX-315 in combination with pembrolizumab in the treatment of advanced melanoma in patients who have failed or are refractory to anti programmed death-protein 1 (PD-1)/anti-programmed death-ligand 1 (PD L1) therapy.

Secondary objectives 2

1. To evaluate the safety and tolerability of LTX-315 in combination with pembrolizumab in patients with advanced melanoma who have failed or are refractory to anti-PD-1/PD-L1 therapy.
2. To explore the pharmacokinetics (PK) of LTX-315 in plasma following intratumoral injection in 20 patients enrolled with advanced melanoma who have failed or are refractory to anti-PD-1/PD-L1 therapy.

Conditions and MedDRA coding

Advanced Melanoma

Study design 3 periods

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 15

1. Have one of the following confirmed histologically: Patients with Stage III B, C, D or Stage IV m1a, m1b unresectable metastatic melanoma who have received an approved anti-PD-1/PD-L1 therapy and have progressed on or after prior anti-PD-1 or anti-PD-L1 therapy, alone or in combination with systemic therapy. For patients who have refused prior standard-of-care treatment other than anti-PD-1/PDL-1, the patient’s reason for refusing standard therapy for their disease shall be clearly documented in the study electronic case report form prior to study participation. All patients must have received anti-PD-1 or anti- PD-L1 in addition to complying with the relevant criteria below. Melanoma patients with BRAF (v-raf murine sarcoma viral oncogene homolog B1) mutation who are eligible and suitable for BRAF inhibitor therapy should have received specific BRAF inhibitor therapy before enrolling in this study and must have completed treatments at least 3 weeks prior to starting treatment and have no signs of rapidly progressive disease (PD). Patients who have refused BRAF inhibitor therapy are also eligible for the study. The patients should have had radiologically PD after the most recent line of systemic therapy (no more than two prior lines in the metastatic setting). Adjuvant or Neoadjuvant therapy is not considered as a prior line or treatment for eligibility purposes. Anti-PD-1 or anti-PD-L1 does not need to be the most recent line of therapy prior to study entry
2. Disease that is not amenable to further radiotherapy or surgery for cancer treatment.
3. Have at least one superficial, non-visceral tumor lesion accessible for injection via cutaneous, subcutaneous, or intramuscular route. Note, lymph nodes with metastatic disease may be selected for injection if they are superficial, but not if deep-seated; visceral lesions must not be selected for injection. The lesion must not be located close to airways, defined as close enough to jeopardize the patient’s safety, in the opinion of the Investigator, in the event of a local reaction to LTX-315 injection (for example, if such a reaction has the potential to interfere with swallowing or result in hemorrhaging into the airways).
4. At least one measurable target lesion evaluable according to RECIST version 1.1 that is not planned to be injected with LTX-315 or biopsied. The location of this noninjected tumor may be superficial, deep-seated, or visceral.
5. Have a life expectancy ≥3 months.
6. Are males or females aged 18 years or older
7. Have an ECOG performance status of 0 or 1.
8. Resolution of all disease or prior treatment-related toxicities to Grade ≤1, with the exception of alopecia, < Grade 2 neuropathy and laboratory abnormalities (parameters below apply). If the patient underwent major surgery or received radiation therapy, they must have fully recovered from the intervention.
9. Have a left ventricular ejection fraction (LVEF) that is above the institution’s lower limit of normal (by echo scan assessment).
10. Meet the following laboratory requirements: a. Absolute neutrophil count ≥1.00 × 109 /L b. Absolute lymphocyte count that is ≥0.5 k/μL or equivalent c. Platelet count ≥75.0 × 109 /L d. Hemoglobin ≥9.0 g/dL e. Prothrombin time/partial thromboplastin time ≤ 1.5 x upper limit of normal (ULN), if the patient is receiving oral anticoagulation international normalized ratio ≤ 1.5 x ULN, activated partial thromboplastin time ≤1.5 x ULN. f. Total bilirubin ≤1.5 x ULN (≤2 x ULN if associated with hepatobiliary metastases or Gilbert’s syndrome) AND associated to the aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 2.5 x ULN. g. AST and ALT ≤2.5 × ULN. h. Calculated creatinine clearance ≥30 mL/min using Cockcroft-Gault formula. i. Lactate dehydrogenase (LDH) ≤ ULN. j. Serum albumin ≥30g/L.
11. Are willing and able to comply with the protocol and agree to return to the clinical site for follow-up visits and examinations.
12. Are willing to undergo tumor biopsy procedures.
13. Are fully informed about the study and have signed the informed consent form.
14. Are willing to use contraceptive measures as prescribed by the protocol. Female patients of childbearing potential and their partners who are sexually active must agree to the use of two highly effective forms of contraception starting from the screening visit, throughout their participation in the study, and for at least 120 days after their last dose of pembrolizumab or at least 180 days after their last dose of LTX-315, whichever is longer. Male patients with partners who are pregnant or of childbearing potential must use a barrier method of contraception starting from the screening visit, throughout their participation in the study and for at least 120 days after their last dose of pembrolizumab or at least 180 days after their last dose of LTX-315, whichever is longer. A woman is considered of childbearing potential, that is, fertile, following menarche and until becoming postmenopausal unless permanently sterile.
15. Female patients must not be pregnant or breastfeeding. Female patients of childbearing potential must have a negative pregnancy test result during screening and at Day 1.

Exclusion criteria 18

1. Patients with primary ocular melanoma or mucosal melanoma are not eligible.
2. Has excessive tumor burden. The patient has more than 10 lesions available for injection, or has any injected lesion > 2cm, or in the opinion of the Investigator. For larger lesions or conglomerate lesions, approval from the sponsor's Medical Monitor is needed prior to enrollment. Patients with more than 10 lesions may be deemed eligible after discussion with the sponsor's Medical Monitor, based on assessment of overall tumor burden.
3. Known bone-only or active central nervous system metastases and/or carcinomatous meningitis. Patients with untreated brain metastases ≤3 mm that are asymptomatic, do not have significant edema, and do not require steroids or anti-seizure medications are eligible after discussion with the sponsor's Medical Monitor. Patients with previously treated brain metastases may participate provided they are stable after treatment and without evidence of progression by imaging for at least 4 weeks prior to the first dose of study drug administration, and are not using corticosteroids for at least 7 days prior to study drug administration
4. Have a history of cerebrovascular or cardiac disorders (e.g., Class III or IV New York Heart Association cardiac failure) and in the investigators’ opinion the patient would be at particular risk of sequelae following a short hypotensive episode.
5. Have a marked baseline prolongation of QT interval corrected for heart rate using Fridericia’s formula (i.e., repeated demonstration of a QTc interval >480 ms National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] Grade 2).
6. Are currently taking immunosuppressive agents or use of systemic corticosteroids or other systemic immunosuppressive drugs within 28 days prior to study drug administration. Patients who require corticosteroids should have been on a stable dose (up to 10 mg daily prednisone or equivalent) for at least 2 weeks prior to study drug administration. Topical and inhaled corticosteroids are also permitted.
7. Have a history of systemic autoimmune disease requiring anti-inflammatory or immunosuppressive therapy within 3 months prior to Day 1, with the following exceptions: a. Patients with a history of autoimmune thyroiditis are eligible provided they require only thyroid hormone replacement therapy and their disease has been stable for ≥1 year. b. Patients with well-controlled type I diabetes (in the opinion of the Investigator) are eligible. c. Patients with a history of chronic disease, who have been stable for the preceding 6 months without treatment
8. Patients who are allergic or have hypersensitivity to chlorpheniramine or equivalent H1 antagonist, cimetidine or equivalent H2 antagonist, or montelukast.
9. Have a history of severe hypersensitivity to another monoclonal antibody; are receiving immunosuppressive therapy; have a history of severe immune-related adverse reaction from treatment with a monoclonal antibody, defined as any Grade ≥3 toxicity requiring corticosteroid treatment (>10 mg/day prednisone or equivalent) for >12 weeks.
10. Have had (non-infectious) pneumonitis Grade ≥3 in the past or current pneumonitis.
11. History of interstitial lung disease.
12. Have a known hypersensitivity to pembrolizumab or LTX-315 or any of their excipients (for pembrolizumab those listed in the prescribing information).
13. Have any other serious illness or medical condition, such as, but not limited to: a. Uncontrolled infection or infection requiring systemic antibiotics b. Uncontrolled cardiac failure: Class III or IV New York Heart Association c. Uncontrolled hypertension or risk factors for uncontrolled hypertension (>160 mmHg systolic and/or >100 mmHg diastolic), despite appropriate antihypertensive medication d. Uncontrolled systemic or gastrointestinal inflammatory conditions e. Known bone marrow dysplasia f. History of positive tests for human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome or active hepatitis B or C (based on serology); positive serology will be confirmed by a viral load test. Patients with treated HIV and a viral load test result consistent with treated HIV, as well as patients with treated hepatitis B or C with an undetectable viral load test result, are eligible g. History of or current mastocytosis.
14. Have received external radiotherapy or cytotoxic chemotherapy within 4 weeks prior to Day 1 or have not recovered (to NCI-CTCAE Grade ≤1; alopecia of any grade is allowed, and peripheral neuropathy of up to Grade 2 is allowed) from AEs due to such agents being administered more than 4 weeks prior to Day 1.
15. Have received cancer immunotherapy within 4 weeks prior to Day 1 or have not recovered from AEs (to NCI-CTCAE Grade ≤1) due to such agents being administered more than 4 weeks prior to Day 1.
16. Have received an investigational drug within 4 weeks prior to Day 1 or are scheduled to receive one during the treatment or post-treatment periods.
17. Are expected to need any other anticancer therapy or immunotherapy to be initiated during the study period.
18. Receipt of any BRAF and/or MEK inhibitor (including any investigational inhibitor) within 3 weeks before first dose of study drug and/or with evidence of rapidly progressive disease.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 3

1. ORR, defined as the proportion of patients who achieved PR and/or CR per local Investigator assessment using RECIST version 1.1
2. CBR, defined as the proportion of patients who respond to treatment, estimated as the proportion of patients who achieve SD, PR, or CR per local Investigator assessment using iRECIST.
3. OS, evaluated as time from baseline until death.

Secondary endpoints 6

1. incidence and severity of AEs (including physical examination findings) related to LTX 315 or to the combination of LTX-315 and pembrolizumab from baseline to end of treatment
2. incidence of clinical laboratory abnormalities based on clinical chemistry, hematology, urinalysis, and coagulation test results
3. change from baseline in vital signs measurements (pulse rate, body temperature, respiration rate)
4. change from baseline in blood pressure measurements
5. change from baseline in 12-lead ECG parameters, including QT interval corrected for heart rate using Fridericia’s formula (QTcF)
6. incidence of LTX-315 injection site assessment findings (injection site pain, swelling, and redness).

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 2

Auxiliary 3

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Lytix Biopharma AS

Sponsor organisation

Lytix Biopharma AS

Address

Sandakerveien 138

City

Oslo

Postcode

0484

Country

Norway

Scientific contact point

Organisation

Lytix Biopharma AS

Contact name

Graeme Currie

Public contact point

Organisation

Lytix Biopharma AS

Contact name

Oystein Redkal

Third parties 7

Locations

3 EU/EEA countries · 5 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Application history

7 submissions — initial application plus substantial / non-substantial modifications